The
hyaluronic acid filler Juvéderm VOLUMA (Allergan) can be used to safely and
effectively correct aesthetically detracting or deficient features of the Asian
nose, with results lasting more than 12 months, according to a new study just
pulished in the Aesthetic Surgery Journal.
This
could be good news, especially in Asia, where rhinoplasty ranks second to
blepharoplasty as the most common procedure performed by plastic surgeons,
according to the study.
Researchers,
including plastic surgeons practicing in Australia and Brazil, as well as
Allergan employees, studied 29 Asian patients whose noses were corrected using
the filler with lidocaine injectable gel. Surgeons used a standardized
injection procedure and patients were followed for more than 12 months.
At the
first follow up visit, 27 of 29 patients had achieved a clinically meaningful
correction of more than or equal to 1 grade improvement on the Assessment of
Aesthetic Improvement Scale. By the final visit, 28 patients had a clinically
meaningful correction, as assessed by the patients and an independent,
non-injecting physician. Nearly 80% (23 patients) reported being satisfied or
very satisfied with the filler treatment; three were neutral and two reported
being very unsatisfied. There was a response missing for one patient.
Twenty-five
of the patients in the study indicated they would recommend the filler
treatment to others.
The
authors conclude that they achieved these levels of success by using specific
eligibility criteria, individualized treatment goals and a standardized
injection procedure. They admit, however, that the most difficult outcome to
achieve with the filler was alar base narrowing and/or nostril shape
alteration.
The study
offers evidence for the use of VOLUMA as a non-surgical alternative in
carefully selected Asian patients unwilling or unable to have surgery, the
authors write.
Among the
possible limitations of the study: its non-comparative and open-label design,
as well as the absence of a quantitative outcome parameter, according to the
authors.
The
Allergan-sponsored clinical study received a level evidence of 3 therapeutic
from its publisher, the Aesthetic Surgery Journal.
No comments:
Post a Comment